Major Psychedelic Compound-Based Research & Development Stocks: June Update

Our munKNEE Psychedelic Drug Stocks Index, has been revamped again with the removal of Cybin (CYBN). CYBN dropped below $100M in market capitalization several months ago and is now trading at $0.22/share, well below the qualifying minimum price of $1/share. That leaves 6 constituents in the Index, which are having for the most part a good month, and a good year. Here's the updated tally for the current index composition.

  1. GH Research (GHRS): up 10.3% MTD; up 28.3% YTD
  2. Compass Pathways (CMPS): up 6.8% MTD; up 0.4% YTD
    • is primarily focused on the use of psilocybin* (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
  3. Mind Medicine (MNMD): up 3.4% MTD; up 71.8% YTD
  4. Incannex Healthcare (IXHL): up 2.1% MTD; down 31.4% YTD
  5. Seelos (SEEL): down 1.0% MTD; up 41.5% YTD
  6. Atai (ATAI); down 2.2% MTD; down 32.2% YTD

*Read 10 Psychedelic Substances And The 36 Companies Researching Them for a description of each of the psychedelic-based compounds mentioned in this article.


The munKNEE Psychedelic Drug Stocks Index is up 6.6% MTD and is now up 10.8% YTD.

If you are interested in this category of clinical-stage psychedelic compound-based stocks consider the  AdvisorShares Psychedelic ETF (PSIL) which consists of 23 such stocks - but keep in mind that the vast majority have market capitalizations of $50M or less (i.e. are nano-caps). It is up 5.9% MTD and is now down 3.2% YTD.

More By This Author:

Canopy Growth Delisting Drags Down Performance Of Canadian Cannabis LPs
BUD Declined Dramatically In May And Again Last Week
5 Largest Cannabis LPs Continue To Go Down, Down, Down

Disclosure: None

Visit and register to receive our free Market Intelligence Report newsletter (sample  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.